Antigen protective agent and application thereof
A protective agent with specific components stabilizes foot-and-mouth disease antigens, addressing degradation issues and cost concerns, ensuring long-term stability and reduced production costs.
Patent Information
- Application Number
- CN202411198143.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing antigen/vaccine stabilizers for foot-and-mouth disease are inadequate in preserving antigen immunogenicity over extended periods, leading to high production and storage costs due to rapid degradation under various environmental and biological factors, and often use expensive materials like bovine serum albumin and trehalose.
A protective agent comprising specific components such as buffer, inorganic salt, surfactant, carbohydrate, sugar alcohol, antioxidant, and protein stabilizer, with a pH range of 7.5-8.0, enhances antigen stability and extends shelf life.
The protective agent provides wide-ranging, cost-effective, and stable antigen preservation, maintaining antigen titer for extended periods, suitable for long-term storage and reducing batch variability.
Smart Images

Figure BDA0005017088470000061 
Figure BDA0005017088470000081
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biopharmaceuticals, and in particular, relates to an antigen protective agent and application thereof. Background Art
[0002] The purpose of foot-and-mouth disease antigen / vaccine stabilizers is to protect antigens and preserve vaccines after emulsification, and to prevent antigens from degrading during production and storage, which may lead to loss of antigen immunogenicity, thereby increasing vaccine production costs and farm immunization costs. Degradable antigens may degrade under external factors, including external physical factors such as temperature, ultraviolet rays, storage conditions, etc. that cause virus / antigen degradation; chemical factors such as pH value, hydrolysis reaction, oxidation reaction, etc.; biological factors such as enzymatic hydrolysis and microbial infection, etc. Therefore, it is necessary to develop protective agents suitable for easily degradable antigens / vaccines.
[0003] At present, there are relevant reports on antigen / vaccine protective agents. For example, Chinese patent CN109106948A discloses a foot-and-mouth disease antigen protective agent and its application, which adopts a Hepes buffer system and adds a variety of sugar substances including fructose, amino acids, proteins and protein disulfide bond reducing agents as the main ingredients of the foot-and-mouth disease antigen protective agent. However, the protection rate of this type of protective agent is only 56% after 9 hours of accelerated aging at 45°C, that is, the protection effect time is short.
[0004] Chinese patent CN10850463 A discloses a method for purifying or storing foot-and-mouth disease virus antigens: in this method, sucrose (up to 20% concentration) and polyhydroxy compounds (such as PEG20000) are added to extend the shelf life of the virus antigen, but this method is not conducive to the emulsification and storage stability of the antigen in the later stage. Chinese patent CN110161237 A discloses a foot-and-mouth disease virus cELISA antibody detection kit with extended shelf life: the kit extends the shelf life of the virus antigen by adding bovine serum albumin (up to 10% concentration) and protective polysaccharides (such as trehalose). However, the raw materials such as bovine serum albumin and trehalose used in this method are expensive, which increases the cost of the antigen and makes it difficult to apply it on a large scale.
[0005] In view of this, the present invention provides an easily degradable antigen protective agent with stronger protective efficacy and lower preparation cost. Summary of the invention
[0006] In view of the problems existing in the prior art, the object of the present invention is to provide an antigen protective agent and application thereof.
[0007] In order to achieve the above object, the present invention adopts the following technical solutions:
[0008] The first aspect of the present invention provides an antigen protective agent, comprising the following components in mass volume percentage: buffer 0.12%-2.4%, inorganic salt 0.1%-5%, surfactant 0.01%-10%, carbohydrate 0.01%-10%, sugar alcohol 0.01%-10%, antioxidant 0.001%-1%, and protein stabilizer 0.001%-1%.
[0009] Preferably, the buffer is selected from any one of a Hepes buffer system, a Tris buffer system, a PB buffer system, a MES buffer system, a citric acid buffer system, and an arginine buffer system.
[0010] Preferably, the inorganic salt is selected from one or a combination of two or more of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium phosphate, potassium phosphate, calcium phosphate, sodium acetate, potassium acetate, and sodium carbonate.
[0011] Preferably, the surfactant is selected from one or a combination of two or more of SDS, TritonX-100, TritonX-114, NP-40, Tween-80, Tween-60, Tween-40, and Tween-20.
[0012] Preferably, the antioxidant is one of DTT (dithiothreitol), mercaptoethanol, TCEP (tris(2-carboxyethyl)phosphine) or a combination of two or more thereof.
[0013] Preferably, the carbohydrate substance is selected from one or a combination of two or more of lactose, trehalose, sucrose, glucose and galactose.
[0014] Preferably, the sugar alcohol is selected from one or a combination of two or more of mannitol, sorbitol, maltitol, polyethylene glycol, xylitol and glycerol.
[0015] Preferably, the protein stabilizer is selected from one or a combination of two or more of glycine, glutamic acid and alanine.
[0016] Preferably, the pH of the antigen protective agent is 7.5-8.0, for example, the pH may be 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, etc.
[0017] The second aspect of the present invention provides a composition containing a foot-and-mouth disease antigen, wherein the composition includes the above-mentioned antigen protective agent.
[0018] Beneficial effects of the present invention:
[0019] The raw materials for preparing the antigen protective agent of the present invention can use a wider range of buffer systems, which can greatly reduce the preparation cost. Experimental results show that the antigen protective agent prepared by the present invention has a wide range of use, small batch differences, stable quality, and a long-lasting protective effect on the foot-and-mouth disease antigen vaccine, and is more suitable for the long-term storage of the foot-and-mouth disease antigen vaccine. DETAILED DESCRIPTION
[0020] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0021] Example 1
[0022] Weigh 0.12 g Tris buffer, 1.17 g sodium chloride, 0.2 g magnesium chloride hexahydrate, 0.05 g Tween-80, 1 g trehalose, 0.2 g sorbitol, 0.01 g EDTA, and 0.1 g glutamic acid, dissolve the above components in water, mix, and make up to 100 mL, then adjust the pH to 7.6, sterilize and filter with a 0.22 μm filter membrane, and store at 4°C.
[0023] Example 2
[0024] Weigh 0.19 g of citric acid buffer (system), 1.17 g of sodium chloride, 0.2 g of magnesium chloride hexahydrate, 0.02 g of Tween-60, 1 g of galactose, 0.2 g of sorbitol, 0.01 g of EDTA, and 0.1 g of glutamic acid, dissolve the above components in water, mix, and make up to 100 mL, then adjust the pH to 7.6, sterilize and filter with a 0.22 μm filter membrane, and store at 4°C.
[0025] Example 3
[0026] Weigh 0.24 g Hepes, 1.17 g sodium chloride, 0.2 g magnesium chloride hexahydrate, 0.05 g Tween-80, 1 g trehalose, 0.2 g sorbitol, 0.01 g EDTA, and 0.1 g glutamic acid, dissolve the above components in water, mix, and make up to 100 mL. Then adjust the pH to 7.6, sterilize and filter with a 0.22 μm filter membrane, and store at 4°C.
[0027] Example 4
[0028] Weigh 0.12 g PB buffer (system), 1.17 g sodium chloride, 0.2 g magnesium chloride hexahydrate, 0.05 g Tween-80, 1 g trehalose, 0.2 g sorbitol, 0.01 g EDTA, and 0.1 g glutamic acid, dissolve the above components in water, mix, and make up to 100 mL, then adjust the pH to 7.6, sterilize and filter with a 0.22 μm filter membrane, and store at 4°C.
[0029] Example 5
[0030] Weigh 0.19 g MES buffer (system), 1.17 g sodium chloride, 0.2 g magnesium chloride hexahydrate, 0.06 g Tween-80, 1 g trehalose, 0.2 g sorbitol, 0.01 g EDTA, and 0.1 g glutamic acid, dissolve the above components in water, mix, and make up to 100 mL, then adjust the pH to 7.6, sterilize and filter with a 0.22 μm filter membrane, and store at 4°C.
[0031] Example 6
[0032] Weigh 0.12 g Tris buffer (system), 1.17 g sodium chloride, 0.2 g magnesium chloride hexahydrate, 0.05 g Tween-60, 1 g trehalose, 0.2 g sorbitol, 0.05 g EDTA, and 0.1 g glutamic acid, dissolve the above components in water, mix, and make up to 100 mL, then adjust the pH to 7.8, sterilize and filter with a 0.22 μm filter membrane, and store at 4°C.
[0033] Comparative Example 1
[0034] The process is substantially the same as Example 1, except that magnesium chloride hexahydrate is not added.
[0035] Comparative Example 2
[0036] The method is substantially the same as Example 1, except that Tween-60 is not added.
[0037] Comparative Example 3
[0038] The process is substantially the same as Example 1, except that sorbitol is not added.
[0039] Comparative Example 4
[0040] Basically the same as Example 1, except that trehalose is not added.
[0041] Comparative Example 5
[0042] The same as Example 1, except that EDTA was not added.
[0043] Comparative Example 6
[0044] The process is substantially the same as Example 1, except that glutamic acid is not added.
[0045] 1. Experimental effectiveness test
[0046] Foot-and-mouth disease antigen type O was tested for stability at different temperatures. The experimental groups were designed as a blank control group, and the experimental groups to which the protective agents prepared in Examples 1-5 were added (respectively recorded as Example 1 group, Example 2 group, Example 3 group, Example 4 group, and Example 5 group) were added. The six groups were then stored at 37°C and 45°C, respectively. Sampling was performed every 7 days with a cycle of 28 days. The test results are shown in Tables 1 and 2.
[0047] Table 1 shows the test results at 37°C
[0048] time Blank control group Example 1 Group Example 2 Group Example 3 Group Example 4 Group Example 5 Group Day 0 32.45μg / ml 32.44μg / ml 32.45μg / ml 32.44μg / ml 32.44μg / ml 32.45μg / ml 7 days 30.25μg / ml 32.43μg / ml 32.43μg / ml 32.42μg / ml 32.43μg / ml 32.43μg / ml 14 days 28.37μg / ml 32.44μg / ml 32.44μg / ml 32.44μg / ml 32.43μg / ml 32.44μg / ml 21 days 24.42μg / ml 32.42μg / ml 32.43μg / ml 32.43μg / ml 32.42μg / ml 32.42μg / ml 28 days 20.26μg / ml 32.43μg / ml 32.43μg / ml 32.42μg / ml 32.43μg / ml 32.44μg / ml
[0049] Table 2 shows the test results at 45°C
[0050] time Blank control group Example 1 Group Example 2 Group Example 3 Group Example 4 Group Example 5 Group Day 0 32.45μg / ml 32.44μg / ml 32.45μg / ml 32.44μg / ml 32.44μg / ml 32.45μg / ml 7 days 0.21μg / ml 22.33μg / ml 23.42μg / ml 22.42μg / ml 23.16μg / ml 22.62μg / ml 14 days 0μg / ml 17.64μg / ml 18.14μg / ml 17.84μg / ml 18.14μg / ml 18.07μg / ml 21 days / 11.82μg / ml 11.23μg / ml 11.43μg / ml 11.64μg / ml 11.57μg / ml 28 days / 6.13μg / ml 7.03μg / ml 7.23μg / ml 7.22μg / ml 7.42μg / ml
[0051] From the results in Table 1 and Table 2, it can be seen that the protective agent prepared in Example 1-5 has little loss of antigenic titer after being stored at 37°C for 28 days; the aging half-life at 45°C is about 14 days, and it can still be detected after being stored for 28 days.
[0052] 2. Key component test of foot-and-mouth disease antigen stabilizer
[0053] The effect of different component deletions on the stability of the protective effect of the foot-and-mouth disease antigen O type was tested. The experimental group design was as follows: the protective agent prepared in Example 6 was the control group, the protective agent prepared in Comparative Example 1 was group one, the protective agent prepared in Comparative Example 2 was group two, the protective agent prepared in Comparative Example 2 was group three, the protective agent prepared in Comparative Example 2 was group four, the protective agent prepared in Comparative Example 2 was group five, and the protective agent prepared in Comparative Example 2 was group six; these 7 groups were stored at 45°C. Sampling was performed for 146s at 6h, 9h and 24h, and the results are shown in Tables 3-5.
[0054] Table 3. Composition of the formula of the control group and groups 1 to 6
[0055] Components Control group Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Tris 0.12 0.12 0.12 0.12 0.12 0.12 0.12 Sodium chloride 1.17 1.17 1.17 1.17 1.17 1.17 1.17 Magnesium chloride 0.2 / 0.2 0.2 0.2 0.2 0.2 Tween-60 0.02 0.02 / 0.02 0.02 0.02 0.02 Sorbitol 0.2 0.2 0.2 / 0.2 0.2 0.2 Trehalose 1.0 1.0 1.0 1.0 / 1.0 1.0 EDTA 0.05 0.05 0.05 0.05 0.05 / 0.05 Glutamate 0.1 0.1 0.1 0.1 0.1 0.1 /
[0056] Table 4. Test results at 45°C
[0057]
[0058]
[0059] From the results in Table 4, it can be seen that the protective agent prepared without adding magnesium chloride (Comparative Example 3), sorbitol (Comparative Example 4), EDTA (Comparative Example 5), and glutamic acid (Comparative Example 6) can only show its effect after being stored at 45°C for 6 hours. Therefore, it can be concluded that in order to achieve the expected technical effect, each component in the protective agent formula is indispensable, and the lack of any one of them will weaken its effect.
[0060] 3. Antigen titer loss test
[0061] The protective agent prepared by the present invention and the commercially available protective agent were placed at 4°C and samples were taken every 2 months to detect the loss of antigen titer. The results are shown in Table 5.
[0062] Table 5. Antigen titer test results at different storage times at 4°C
[0063] Placement time Commercially available protective agent Example 6 0 32.45μg / ml 32.45μg / ml 2 months 32.32μg / ml 32.44μg / ml 4 months 32.06μg / ml 32.44μg / ml 6 months 31.63μg / ml 32.38μg / ml 8 months 30.51μg / ml 31.85μg / ml 10 months 29.04μg / ml 31.29μg / ml 12 months 27.39μg / ml 30.51μg / ml
[0064] From the results in Table 5, it can be seen that the currently available foot-and-mouth disease antigen protective agent has a good protective effect at 4°C. Generally, the antigen titer loss is within 20% after being placed for 12 months; while the foot-and-mouth disease antigen protective agent prepared by the present invention has an antigen titer loss of less than 10% after being placed for 12 months at 4°C.
[0065] 4. Antigen shelf life test
[0066] The protective agent prepared in Example 6 of the present invention was added to the foot-and-mouth disease antigen and emulsified into a vaccine according to the emulsification process. The shelf life test was then conducted. Sampling was performed every 3 months. The water phase was measured for 146s after demulsification and compared with the commercial protective agent. The results are shown in Table 6.
[0067] Table 6. Antigen shelf life test results
[0068] Placement time Commercially available protective agent Example 6 0 32.45μg / ml 32.45μg / ml 3 months 31.05μg / ml 32.39μg / ml 6 months 29.82μg / ml 32.14μg / ml 9 months 26.72μg / ml 30.98μg / ml 12 months 24.56μg / ml 29.85μg / ml
[0069] It can be seen from the results in Table 6 that, compared with commercially available protective agents, the foot-and-mouth disease antigen protective agent prepared by the present invention has a stronger protective effect on antigens.
[0070] 5. Antigen safety testing
[0071] The commercially available antigen protective (stabilizing) agent and the protective (stabilizing) agent prepared in Example 6 of the present invention were emulsified into water-in-oil-in-water vaccines according to the same emulsification method, and then immunized guinea pigs and piglets according to the veterinary pharmacopoeia method. The animal safety test method of the Chinese Veterinary Pharmacopoeia was used for testing.
[0072] The results are shown in Table 7.
[0073] Table 7. Safety test results
[0074]
[0075] It can be seen from the results in Table 7 that the antigen protective agent prepared by the present invention has good safety performance.
[0076] In summary, the antigen vaccine protective agent prepared by the present invention has a wide range of applications, small batch differences, low production costs, and long protective efficacy, and is therefore suitable for long-term storage of foot-and-mouth disease antigen vaccines.
[0077] The above contents are merely examples and explanations of the present invention. Those skilled in the art may make various modifications or additions to the specific embodiments described or replace them in a similar manner. As long as they do not deviate from the invention or exceed the scope defined by the claims, they shall all fall within the protection scope of the present invention.
Claims
1. An antigen protective agent, characterized in that The components are in the following mass volume percentages: buffer 0.12%-2.4%, inorganic salt 0.1%-5%, surfactant 0.01%-10%, carbohydrate 0.01%-10%, sugar alcohol 0.01%-10%, antioxidant 0.001%-1%, and protein stabilizer 0.001%-1%.
2. The antigen protective agent according to claim 1, characterized in that The buffer is selected from any one of a Hepes buffer system, a Tris buffer system, a PB buffer system, a MES buffer system, a citric acid buffer system, and an arginine buffer system.
3. The antigen protective agent according to claim 1, characterized in that The inorganic salt is selected from one or a combination of two or more of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium phosphate, potassium phosphate, calcium phosphate, sodium acetate, potassium acetate, and sodium carbonate.
4. The antigen protective agent according to claim 1, characterized in that The surfactant is selected from one of SDS, TritonX-100, TritonX-114, NP-40, Tween-80, Tween-60, Tween-40, Tween-20, or a combination of two or more thereof.
5. The antigen protective agent according to claim 1, characterized in that The antioxidant is one of DTT, mercaptoethanol, and TCEP, or a combination of two or more thereof.
6. The antigen protective agent according to claim 1, characterized in that The sugar substance is selected from one of lactose, trehalose, sucrose, glucose and galactose or a combination of two or more thereof.
7. The antigen protective agent according to claim 1, characterized in that The sugar alcohol is selected from one or a combination of two or more of mannitol, sorbitol, maltitol, polyethylene glycol, xylitol and glycerol.
8. The antigen protective agent according to claim 1, characterized in that The protein stabilizer is selected from one or a combination of two or more of glycine, glutamic acid and alanine.
9. The antigen protective agent according to claim 1, characterized in that The pH of the protective agent is 7.5-8.
0.
10. A composition containing foot-and-mouth disease antigen, characterized in that: Comprising the antigen protective agent according to any one of claims 1 to 9.
Citation Information
Patent Citations
Foot-and-mouth disease antigen protection agent and application thereof
CN109106948A
Foot-and-mouth disease virus cELISA antibody detection reagent kit for extending preservation period
CN110161237A
Foot-and-mouth disease virus antigen protective agent
CN110161238A
Antigen stabilizer
CN111272991A
Chimpanzee adenovirus vector-based liquid vaccine formulation and preparation method
WO2024032626A1
